ISSUE ONE (Jan - Mar) 2017 HTML
| INDEXES ALL VOLUMES
BUY THE PDF OF THIS ISSUEFOR £6.00GO TO HTML COVER PAGE FORCREDIT/DEBIT CARD PURCHASE OPTIONS
HUMANITIES SCIENCE POLITICS
Science, People & Politics ISSN 1751-598X
NEWS | 7
than to words developed for litigation. By "The Time" the judges mean when UC inventors
published their research in Science [Jinek et al] in August 2012(1).
The judges write,
"... we are still persuaded by Dr Carroll's statement made contemporaneously to Jinek 2012
'There is no guarantee that cas9 will work effectively on a chromatin target or that the required
DNA-RNA hybrid can be stabilized in that context... Only attempts to apply the system in
eukaryotes will address these concerns."
Though cited by the judges in support of their finding for the Broad, Dr Carroll was UC's expert
witness. The judges write also that a scientist's enthusiasm for their own work is not a
convincing argument that CRISPR-cas9 had an obvious chance of success in eukaryotes. Nor
did they accept that because the application of CRISPR-cas9 had worked in eukaryotes that
that meant it was obvious it would work.
*CRISPR-cas is an acronym for Clustered Regularly Interspersed Short Palindromic Repeats
associated with Cas. Cas is a protein.
(1). Jinek et al (2012). "A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive
Bacterial Immunity", Science 337 pp 816-821 DOI: 10.1126/science.1225829
Helen Gavaghan edited the patents page in the technology section of New Scientist for three
years as one of her duties during the 7 years she was on staff at the magazine.
The next issue of
Friday 26th May 2017
Issue 1 (Jan-Mar), 2017............................................Science, People & Politics ISSN 1751-598X print and online
Published Friday 24th February, 2017,
nominally.Completed 9th April, 2017.
HTML/CSS by Helen Gavaghan©